Cash and cash equivalents were approximately $96.7 million as of March 31, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKUR:
- OnKure Therapeutics initiated with an Outperform at Evercore ISI
- OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright
- Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue